Special Series: Obesity and GLP-1 Medications

       

Topics covered in this series

Welcome to the Obesity and GLP-1 Medications Special Series

In this series, you will find:

 

Letter from guest editor Wudeneh Mulugeta, MD, MPH

Published March 2025

Glucagon-like peptide-1 (GLP-1) receptor agonists have rapidly become the most prescribed medications in the US, primarily due to their effectiveness in treating obesity. This surge in popularity appears to have caught the health care system off guard, from drug manufacturers and insurance companies to regulators, pharmacies, primary care practitioners, and patients. While most primary care providers lack additional training in weight management, high patient demand is driving them to adapt their practices and address obesity within primary care settings. GLP-1 receptor agonists offer significant benefits for suitable patients, but widespread advertising and misinformation on social media and through personal anecdotes have overwhelmed the general public. This special series aims to provide balanced information from key stakeholders including patients, primary care physicians, obesity specialists, and pharmacists with diverse expertise. While based on the latest evidence and expert opinion, this series is not exhaustive. The information surrounding GLP-1 receptor agonists in particular is constantly evolving as new data emerges and the health care system adjusts to ensure their safe and effective utilization. It is also imperative to acknowledge the impact of social determinants of health, weight bias, and the interconnectedness of clinical and cultural concerns on this complex topic.
 
From the editors: A note on language  

We wish to acknowledge the complexity of the term “obesity” and language around this topic. “Obesity” is a medical diagnosis based on body mass index, which identifies people as having this medical condition based solely on their body size and has significant shortcomings as a clinical tool. Different terms may be preferred by individuals, including “fat,” “overweight,” “big,” “heavy,” “higher-weight,” “unhealthy weight,” and others. Unsurprisingly, this is an area of debate both within medicine and in the general public. However, it is important to note that the word “obesity is felt by many to be stigmatizing, and that many people at higher weights have experienced bias and discrimination not just by society at large, but by medical professionals. Some also feel that World Obesity Day itself perpetuates weight bias and stigma. In putting together this special issue, it is not our intent to contribute to this stigma, only to contribute to knowledge. Please reach out to the editorial team if you have any concerns, and we welcome articles with differing perspectives by all readers regardless of background. 

For more reading on the language and advocacy around these issues, we recommend the following: 


 

Join us for a virtual event

Friday, March 28, 10-11 a.m. ET

As GLP-1 and GLP-1/GIP receptor agonist use becomes more common, it is important to stay up to date on the latest clinical guidance. During this virtual event, we will talk with a primary care physician who is board-certified in obesity medicine, a pediatric endocrinologist, and a clinical psychologist to cover different aspects of obesity medicine and best practices GLP-1 medication use.


 

Special series articles

Please note these articles will be published on a rolling basis throughout March 2025. To receive a notification of new articles, sign up for alerts at the bottom of this page.

Clinical Considerations

Update in weight management within primary care in the era of GLP-1 

Learn the latest guidelines for Primary Care
Article By: Wudeneh Mulugeta, MD, MPH

 

Mental Health

Forthcoming

 

Equity

Forthcoming

 

Personal Perspective

Forthcoming

 

Misinformation

Forthcoming

Series editors 

  • Wudeneh Mulugeta, MD, MPH, Guest Editor
  • Ananya Tadikonda, Scholarship Specialist
  • Leena Ambady, Associate Editor
  • Karl Singer, MD, Associate Editor
  • Katie Cavender, MBA, Managing Editor
  • Zoe Agoos, MD, Editor-in-Chief 

Receive new content alerts